Rana Mckay, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Non-urology Healthcare Related)
    Ineligible company:
    Bayer
    Date added:
    Date updated:
    04/05/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Novartis
    Date added:
    Date updated:
    04/05/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Exelixis
    Date added:
    Date updated:
    04/05/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Janssen
    Date added:
    Date updated:
    04/05/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Non-urology Healthcare Related)
    Ineligible company:
    BMS
    Date added:
    Date updated:
    04/05/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Non-urology Healthcare Related)
    Ineligible company:
    Tempus
    Date added:
    Date updated:
    04/05/2023
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Oncology)
    Ineligible company:
    Aveo
    Date added:
    Date updated:
    04/05/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Calithera
    Date added:
    Date updated:
    04/05/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Telix
    Date added:
    Date updated:
    04/05/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    SeaGen
    Date added:
    Date updated:
    04/05/2023

Pages

Return to Advances in ADT: Part II: A Guide for APPs (2023)